MYC Is a Major Determinant of Mitotic Cell Fate

Caroline Topham, Anthony Tighe, Peter Ly, Ailsa Bennett, Olivia Sloss, Louisa Nelson, Rachel A. Ridgway, David Huels, Samantha Littler, Claudia Schandl, Ying Sun, Beatrice Bechi, David J. Procter, Owen J. Sansom, Don W. Cleveland, Stephen S. Taylor

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible for patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression. Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination therapies that could enhance traditional and second-generation antimitotic agents.

Original languageEnglish (US)
Pages (from-to)129-140
Number of pages12
JournalCancer Cell
Volume28
Issue number1
DOIs
StatePublished - Jul 13 2015
Externally publishedYes

Fingerprint

Antimitotic Agents
Paclitaxel
Time-Lapse Imaging
Small Interfering RNA
Transcription Factors
Biomarkers
Genome
Pharmacology
Apoptosis
Breast Neoplasms
Gene Expression
Drug Therapy
Survival
Proteins
Therapeutics
taxane

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Topham, C., Tighe, A., Ly, P., Bennett, A., Sloss, O., Nelson, L., ... Taylor, S. S. (2015). MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell, 28(1), 129-140. https://doi.org/10.1016/j.ccell.2015.06.001

MYC Is a Major Determinant of Mitotic Cell Fate. / Topham, Caroline; Tighe, Anthony; Ly, Peter; Bennett, Ailsa; Sloss, Olivia; Nelson, Louisa; Ridgway, Rachel A.; Huels, David; Littler, Samantha; Schandl, Claudia; Sun, Ying; Bechi, Beatrice; Procter, David J.; Sansom, Owen J.; Cleveland, Don W.; Taylor, Stephen S.

In: Cancer Cell, Vol. 28, No. 1, 13.07.2015, p. 129-140.

Research output: Contribution to journalArticle

Topham, C, Tighe, A, Ly, P, Bennett, A, Sloss, O, Nelson, L, Ridgway, RA, Huels, D, Littler, S, Schandl, C, Sun, Y, Bechi, B, Procter, DJ, Sansom, OJ, Cleveland, DW & Taylor, SS 2015, 'MYC Is a Major Determinant of Mitotic Cell Fate', Cancer Cell, vol. 28, no. 1, pp. 129-140. https://doi.org/10.1016/j.ccell.2015.06.001
Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L et al. MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell. 2015 Jul 13;28(1):129-140. https://doi.org/10.1016/j.ccell.2015.06.001
Topham, Caroline ; Tighe, Anthony ; Ly, Peter ; Bennett, Ailsa ; Sloss, Olivia ; Nelson, Louisa ; Ridgway, Rachel A. ; Huels, David ; Littler, Samantha ; Schandl, Claudia ; Sun, Ying ; Bechi, Beatrice ; Procter, David J. ; Sansom, Owen J. ; Cleveland, Don W. ; Taylor, Stephen S. / MYC Is a Major Determinant of Mitotic Cell Fate. In: Cancer Cell. 2015 ; Vol. 28, No. 1. pp. 129-140.
@article{215273a710204baba5b018aaf5a0788c,
title = "MYC Is a Major Determinant of Mitotic Cell Fate",
abstract = "Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible for patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression. Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination therapies that could enhance traditional and second-generation antimitotic agents.",
author = "Caroline Topham and Anthony Tighe and Peter Ly and Ailsa Bennett and Olivia Sloss and Louisa Nelson and Ridgway, {Rachel A.} and David Huels and Samantha Littler and Claudia Schandl and Ying Sun and Beatrice Bechi and Procter, {David J.} and Sansom, {Owen J.} and Cleveland, {Don W.} and Taylor, {Stephen S.}",
year = "2015",
month = "7",
day = "13",
doi = "10.1016/j.ccell.2015.06.001",
language = "English (US)",
volume = "28",
pages = "129--140",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - MYC Is a Major Determinant of Mitotic Cell Fate

AU - Topham, Caroline

AU - Tighe, Anthony

AU - Ly, Peter

AU - Bennett, Ailsa

AU - Sloss, Olivia

AU - Nelson, Louisa

AU - Ridgway, Rachel A.

AU - Huels, David

AU - Littler, Samantha

AU - Schandl, Claudia

AU - Sun, Ying

AU - Bechi, Beatrice

AU - Procter, David J.

AU - Sansom, Owen J.

AU - Cleveland, Don W.

AU - Taylor, Stephen S.

PY - 2015/7/13

Y1 - 2015/7/13

N2 - Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible for patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression. Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination therapies that could enhance traditional and second-generation antimitotic agents.

AB - Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible for patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression. Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination therapies that could enhance traditional and second-generation antimitotic agents.

UR - http://www.scopus.com/inward/record.url?scp=84937401224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937401224&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.06.001

DO - 10.1016/j.ccell.2015.06.001

M3 - Article

C2 - 26175417

AN - SCOPUS:84937401224

VL - 28

SP - 129

EP - 140

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -